Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
Table 4
Factors related to the improvement of eGFR (CKD-EPI) (increase in eGFR > 10%) according to univariate and multivariate logistic regressions.
Risk factor
Univariate
value
Multivariate
value
HR (95% CI)
HR (95%CI)
Age: ≥50 years
2.221 (1.070–4.611)
0.032
1.315 (0.576–3.001)
0.516
Sex: male
0.987 (0.423–2.305)
0.976
HBeAg: positive
0.663 (0.308–1.427)
0.293
Cirrhosis
0.785 (0.333–1.849)
0.580
Decompensation
0.929 (0.342–2.520)
0.885
Hepatocellular carcinoma
1.101 (0.338–3.583)
0.873
HBV genotype: type B
0.518 (0.222–1.209)
0.128
Baseline ALT > 200 U/L
1.031 (0.494–2.154)
0.935
Baseline HBV DNA: <7 log IU/mL
1.222 (0.564–2.650)
0.611
Baseline eGFR < 60 mL/min/1.73 m2
7.117 (1.849–27.399)
0.004
4.560 (1.046–19.875)
0.043
Diabetes mellitus
5.958 (1.776–19.993)
0.004
4.194 (1.165–15.098)
0.028
Hypertension
0.931 (0.436–3.874)
0.864
Add-on adefovir therapy
0.477 (0.186–1.222)
0.123
Complete virological response at month 6
1.670 (0.778–3.585)
0.189
Contrast medium exposure
1.101 (0.338–3.583)
0.873
ALT: alanine transaminase; HBeAg: hepatitis B e-antigen; HR: hazard ratio.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
